An autologous tumor infiltratating lymphocite therapy for the treatement of advanced melanoma

WEST WARWICK, Rhode Island
April, 2023

Iovance Biotherapeutics, Inc. completes their BLA submission for Lifileucel – an autologous tumor infiltrating lymphocyte (TIL) therapy (manufactured using PBMC feeder cells) for the treatment of advanced (unresectable or metastatic) melanoma who have progressed on or after prior anti-PD-1/L1 therapy and targeted therapy, where applicable. There are no FDA approved therapies in this treatment setting. Furthermore, this is the first TIL cell therapy BLA submission ever submitted to the FDA. Here’s to a bright future for these patients, Iovance, and all involved!

About Blood Centers of America
 Blood Centers of America (BCA) is a member-owned organization comprised of over 50 independent blood centers throughout the North America, representing nearly 40% of the U.S. blood supply. Along with their core business of providing a substantial portion of U.S. blood supply, other BCA member services include patient blood management, transfusion services, immunohematology testing, therapeutic apheresis and tissue and cord blood banking. In addition, BCA members provide a variety of human blood products, cells and tissues to the therapeutic, diagnostic and cell therapy industries.